Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients

BACKGROUND: Sipuleucel-T is an autologous cellular immunotherapy that is FDA approved for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). The IMPACT registry trial demonstrated a 4.1 month survival benefit, but not a consistent PSA respon...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate Cancer Prostatic Dis
Autors principals: Holl, Eda K., McNamara, Megan A., Healy, Patrick, Anand, Monika, Concepcion, Raoul S., Breland, Coleman D., Dumbudze, Igor, Tutrone, Ron, Shore, Neal, Armstrong, Andrew J., Harrison, Michael, Wallace, Joe A., Wu, Yuan, George, Daniel J.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853838/
https://ncbi.nlm.nih.gov/pubmed/30980027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-019-0144-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars